Supporting Information:

Construction of Chiral 1,3-Diamines through Rhodium-Catalyzed Asymmetric Arylation of Cyclic N-Sulfonyl Imines

Chun-Yan Wu,† and Ming-Hua $\mathrm{Xu}^{*\dagger\ddagger}$

[†]State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences,555 Zuchongzhi Road, Shanghai 201203, China.
[‡]Shenzhen Grubbs Institute and Department of Chemistry, Southern University of Science and Technology, 1088 Xueyuan Blvd., Shenzhen 518055, China.
E-mail: xumh@simm.ac.cn; xumh@sustech.edu.cn

Table of contents

1. General	S2
2. General procedure for synthesis of substrate	S2
3. General procedure for Rh-catalyzed 1, 2-arylation of cyclic N-sulfonyl	
imines	S2
4. Characterization data and HPLC chromatogram of addition products	S4
5. Construction of chiral 1,3-diamines	S26
6. Copies of ¹ H NMR and ¹³ C NMR spectra of products	S35

1. General

All anaerobic and moisture-sensitive manipulations were carried out with standard Schlenk techniques under predried nitrogen or argon. Solvents were dried and distilled by standard procedures. NMR spectra were recorded on a Mercury 300 spectrometer (300 MHz for ¹H), Variant EM 390 (400 MHz for 1H), and Varian spectrometer (300 MHz for ¹H, 125 MHz, 150 MHz for ¹³C). Chemical shifts are reported in δ ppm referenced to an internal SiMe₄ standard for ¹H NMR and chloroform-*d* (δ 77.36) for ¹³C NMR. HRMS were recorded on a Q-TOF mass spectrometer with ESI resource or Magnetic Sector for EI. Optical rotations were measured on a Perkin-Elmer 241 MC polarimeter. HPLC was performed on a JASCO 2000 instrument by using Daicel columns with 2-propanol/hexane as the eluent.

2. General procedure for synthesis of substrate



Dry hydrogen chloride was bubbled through a solution of sulfamide (1 equiv.) and 1,1,3,3-tetramethoxypropane (1 equiv.) in ethanol at room temperature for 15 min, and the mixture was heated under reflux for 6 h. Then, the solvent was evaporated and the residue redissolved in ethanol. Potassium *t*-butoxide (1 equiv.) was added at room temperature in small portions, and the reaction was heated at 80 °C for 10 min, cooled and filtered to afford the intermediate residue. Dissolved the intermediate in DMSO and added 1 equiv. halide, the reaction was stirred at 50 °C for 3 h. Cooled the mixture to room temperature and extracted with EA, washed with water, dried on anhydrous Na₂SO₄ and removed the solvent under vacuum, the residue was purified by silica gel column chromatography to afford the substrate as white solid.

The substrate was chlorinated by *N*-chlorosuccinimide (1.2 equiv.) and brominated by *N*-bromosuccinimide (1.2 equiv.) in DCM to afford the 4-position halide substrates. The 4-vinyl and 4-phenyl subatrates could be obtained through $Pd(PPh_3)_2Cl_2$ (5 mol %) catalyzed coupling reactions with tributyl(vinyl)tin (1 equiv.) and tributyl(phenyl)tin (1 equiv.) in DCE at 50 °C.

3. General procedure for Rh-catalyzed 1,2-arylation of cyclic N-sulfonyl imines



Under Ar atmosphere, a solution of cyclic *N*-sulfonyl imine (0.20 mmol), $[Rh(COE)_2Cl]_2$ (2.5 mol %, 3.6 mg, 0.01 mmol of Rh), **L3** (3.0 mg, 5 mol %, 0.01 mmol), and arylboronic acid **2** (0.40 mmol) in 2.0 mL of toluene was stirred at room temperature for 30 min. To this mixture was added aqueous KOH (0.2 mL, 1.5 M, 0.30 mmol) and then the resulting mixture was stirred at 60 °C for 2 ~ 15 hours. The solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography using petroleum ether/ethyl acetate to afford the corresponding addition product **3**.

Representative example at 1 mmol scale:



Under Ar atmosphere, a solution of cyclic *N*-sulfonyl imine **1a** (1.0 mmol), $[Rh(COE)_2Cl]_2$ (2.5 mol %, 18 mg, 0.05 mmol of Rh), **L3** (15 mg, 5 mol %, 0.05 mmol), and phenylboronic acid **2b** in 10 mL of toluene was stirred at room temperature for 30 min. To this mixture was added aqueous KOH (1 mL, 1.5 M, 1.5 mmol) and then the resulting mixture was stirred at 60 °C for 3 hours. The solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography using petroleum ether/ethyl acetate to afford the addition product **3b** (95% yield, 99% ee).

4. Characterization data and HPLC of addition products

(S)-6-benzyl-3-(4-methoxyphenyl)-3,6-dihydro-2H-1,2,6-thiadiazine 1,1-dioxide (3a)

White solid, 58 mg, 88% yield, 99% ee. $[\alpha]^{20}_{D} = -47.3$, (c 0.38, CHCl₃). ¹H NMR (300 MHz, CDCl₃) δ 7.41 - 7.34 (m, 5H), 7.21 - 7.17 (m, 2H), 6.89 - 6.84 (m, 2H), 6.10 (dd, J = 8.5, 2.1 Hz, 1H), 5.29 (d, J = 9.8 Hz, 1H), 5.09 (dd, J = 8.5, 1.8 Hz, 1H), 4.60 (dd, J = 96.2, 14.9 Hz, 2H), 3.80 (s, 3H), 3.77 (s, 1H). ¹³C

NMR (125 MHz, CDCl₃) δ 160.3, 135.6, 130.7, 130.1, 129.3, 129.2, 129.1, 128.6, 114.7, 108.2, 60.0, 55.7, 52.5. HRMS (ESI) for C₁₇H₁₈N₂NaO₃S [M+Na]⁺: calcd 353.0930, found 353.0925.

HPLC: Chiralcel AD-H column (250 mm); detected at 254 nm; hexane/*i*-propanol = 70/30; flow =0.7 mL/min; Retention time: 11.4 min, 13.7 min (major).



(S)-6-benzyl-3-phenyl-3,6-dihydro-2H-1,2,6-thiadiazine 1,1-dioxide (3b)



White solid, 59.4 mg, 99% yield, 99% ee. $[\alpha]^{20}_{D}$ = -40.0, (c 1.14, CHCl₃). ¹H NMR (300 MHz, CDCl₃) δ 7.41 - 7.34 (m, 8H), 7.27 (dd, J = 6.7, 2.5 Hz, 2H), 6.11 (dd, J = 8.5, 2.1 Hz, 1H), 5.36 - 5.32 (m, 1H), 5.11 (dd, J = 8.5, 1.8 Hz, 1H), 4.60 (dd, J = 90.7, 15.0 Hz, 2H), 3.87 (d, J = 9.9 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 138.1, 135.6, 130.9, 129.4, 129.3, 129.2, 129.1, 128.6, 128.0, 107.9, 60.5, 52.6. HRMS (ESI)

for C₁₆H₁₆N₂NaO₂S [M+Na]⁺: calcd 323.0825, found 323.0824.

HPLC: Chiralcel AD-H column (250 mm); detected at 254 nm; hexane/*i*-propanol = 70/30; flow =0.7 mL/min; Retention time: 8.1 min, 9.3 min (major).



(S)-6-benzyl-3-(p-tolyl)-3,6-dihydro-2H-1,2,6-thiadiazine 1,1-dioxide (3c)



White solid, 60.2 mg, 96% yield, 99% ee.
$$[\alpha]^{20}{}_{D} = -42.3$$
 (c 0.62, CHCl₃). ¹H NMR (300 MHz, CDCl₃) δ 7.41 - 7.34 (m, 5H), 7.17 - 7.12 (m, 4H), 6.10 (dd, $J = 8.5, 2.1$ Hz, 1H), 5.30 (dt, $J = 10.0, 1.9$ Hz, 1H), 5.09 (dd, $J = 8.5, 1.8$ Hz, 1H), 4.60 (dd, $J = 95.1, 14.9$ Hz, 2H), 3.81 (d, $J = 10.0$ Hz, 1H), 2.34 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 139.2, 135.6, 135.1, 130.7, 130.1, 129.2, 129.1, 128.6,

127.9, 108.2, 60.3, 52.6, 21.5. HRMS (ESI) for $C_{17}H_{18}N_2NaO_2S$ [M+Na]⁺: calcd 337.0981, found 337.0988.

HPLC: Chiralcel AD-H column (250 mm); detected at 254 nm; hexane/*i*-propanol = 70/30; flow =0.7 mL/min; Retention time: 8.7 min, 10.4 min (major).



(S)-6-benzyl-3-(4-chlorophenyl)-3,6-dihydro-2H-1,2,6-thiadiazine 1,1-dioxide (3d)



White solid, 66.1 mg, 99% yield, 99% ee. $[\alpha]^{20}_{D} = -39.4$ (c 0.98, CHCl₃). ¹H NMR (300 MHz, CDCl₃) δ 7.40 - 7.31 (m, 7H), 7.20 (d, J = 8.5 Hz, 2H), 6.13 (dd, J = 8.5, 2.0 Hz, 1H), 5.31 (d, J = 9.9 Hz, 1H), 5.08 (dd, J = 8.5, 1.8 Hz, 1H), 4.60 (dd, J = 87.2, 15.0 Hz, 2H), 3.84 (d, J = 9.7 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 136.5, 135.4, 135.2, 131.2, 129.6, 129.4, 129.3, 129.1, 128.7, 107.4, 59.8, 52.6.

HRMS (ESI) for $C_{16}H_{15}CIN_2NaO_2S$ [M+Na]⁺: calcd 357.0435, found 357.0434.

HPLC: Chiralcel AD-H column (250 mm); detected at 254 nm; hexane/*i*-propanol = 70/30; flow =0.7 mL/min; Retention time: 8.6 min, 9.4 min (major).



(S)-6-benzyl-3-(4-fluorophenyl)-3,6-dihydro-2H-1,2,6-thiadiazine 1,1-dioxide (3e)



White solid, 63 mg, 99% yield, 99% ee. $[\alpha]^{20}_{D} = 1.7$ (c 0.44, CHCl₃). ¹H NMR (300 MHz, CDCl₃) δ 7.40 - 7.35 (m, 5H), 7.28 - 7.23 (m, 2H), 7.06 - 7.01 (m, 2H), 6.14 - 6.10 (m, 1H), 5.32 (d, J = 9.8 Hz, 1H), 5.09 (dd, J = 8.5, 1.8 Hz, 1H), 4.60 (dd, J = 88.6, 15.0 Hz, 2H), 3.84 (d, J = 9.8 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 163.2 (d, $J_{CF} = 247$ Hz), 135.5, 133.9 (d, $J_{CF} = 3.1$ Hz), 131.1, 129.9 (d, $J_{CF} = 8.4$

Hz), 129.2, 129.1, 128.7, 116.3 (d, $J_{CF} = 21.6$ Hz), 107.6, 59.8, 52.6. HRMS (ESI) for $C_{16}H_{15}FN_2NaO_2S$ [M+Na]⁺: calcd 341.0730, found 341.0730.

HPLC: Chiralcel AD-H column (250 mm); detected at 254 nm; hexane/*i*-propanol = 70/30; flow =0.7 mL/min; Retention time: 8.2 min, 8.5 min (major).



(S)-6-benzyl-3-(4-(trifluoromethyl)phenyl)-3,6-dihydro-2H-1,2,6-thiadiazine 1,1-dioxide (3f)



White solid, 44.2 mg, 60% yield, 98% ee. $[\alpha]^{20}_{D} = -23.4$ (c 0.71, CHCl₃). ¹H NMR (300 MHz, CDCl₃) δ 7.62 (d, J = 8.0 Hz, 2H), 7.42 - 7.36 (m, 7H), 6.16 (d, J = 8.5 Hz, 1H), 5.38 (d, J = 7.3 Hz, 1H), 5.11 (d, J = 8.5 Hz, 1H), 4.62 (dd, J = 78.3, 15.0 Hz, 2H), 3.96 (d, J = 9.3 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 141.9, 135.4, 131.5 (q, $J_{CF} = 32.5$ Hz), 131.4, 129.3, 129.1, 128.8, 128.4, 126.3

(d, $J_{CF} = 3.6$ Hz), 124.1 (q, $J_{CF} = 270$ Hz), 106.9, 59.9, 52.7. HRMS (ESI) for $C_{17}H_{15}F_3N_2NaO_2S$ [M+Na]⁺: calcd 391.0699, found 391.0701.

HPLC: Chiralcel AD-H column (250 mm); detected at 254 nm; hexane/*i*-propanol = 70/30; flow =0.7 mL/min; Retention time: 7.1 min, 7.7 min (major).



(S)-6-benzyl-3-(3-methoxyphenyl)-3,6-dihydro-2H-1,2,6-thiadiazine 1,1-dioxide (3g)



White solid, 60.0 mg, 91% yield, 99% ee. $[\alpha]^{20}_{D} = -52.6$ (c 1.19, CHCl₃). ¹H NMR (300 MHz, CDCl₃) δ 7.40 - 7.24 (m, 6H), 6.89 - 6.84 (m, 3H), 6.10 (dt, J = 8.5, 1.9Hz, 1H), 5.33 - 5.29 (m, 1H), 5.10 (dd, J = 8.5, 1.8 Hz, 1H), 4.60 (ddd, J = 87.1, 15.0, 1.7 Hz, 2H), 3.92 (d, J = 9.9 Hz, 1H), 3.79 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 160.4, 139.5 135.6, 130.8, 130.5, 129.2, 129.0, 128.6, 120.1, 114.8, 113.7,

107.7, 60.4, 55.7, 52.5. HRMS (ESI) for C₁₇H₁₈N₂NaO₃S [M+Na]⁺: calcd 353.0930, found 353.0932.

HPLC: Chiralcel AD-H column (250 mm); detected at 254 nm; hexane/*i*-propanol = 70/30; flow =0.7 mL/min; Retention time: 9.4 min, 11.7 min (major).



(S)-6-benzyl-3-(m-tolyl)-3,6-dihydro-2H-1,2,6-thiadiazine 1,1-dioxide (3h)



White solid, 59 mg, 94% yield, 98% ee. $[\alpha]^{20}_{D} = -19.0$ (c 0.47, CHCl₃). ¹H NMR (300 MHz, CDCl₃) δ 7.42 - 7.33 (m, 5H), 7.27 - 7.22 (m, 1H), 7.15 (d, J = 7.5 Hz, 1H), 7.08 - 7.07 (m, 2H), 6.11 (dd, J = 8.5, 2.0 Hz, 1H), 5.30 (d, J = 9.9 Hz, 1H), 5.10 (dd, J = 8.5, 1.7 Hz, 1H), 4.79 - 4.43 (m, 2H), 3.92 (s, 1H), 2.35 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 139.2, 137.9, 135.5, 130.6, 130.0, 129.2, 129.1, 129.0, 128.6, 125.0,

108.2, 60.5, 52.5, 21.7. HRMS (ESI) for $C_{17}H_{18}N_2NaO_2S$ [M+Na]⁺: calcd 337.0981, found 337.0984.

HPLC: Chiralcel AD-H column (250 mm); detected at 254 nm; hexane/*i*-propanol = 70/30; flow =0.7 mL/min; Retention time: 7.3 min, 8.4 min (major).



(S)-6-benzyl-3-(3-chlorophenyl)-3,6-dihydro-2H-1,2,6-thiadiazine 1,1-dioxide (3i)



White solid, 60.1 mg, 90% yield, 99% ee. $[\alpha]^{20}_{D} = -23.2$ (c 0.45, CHCl₃). ¹H NMR (300 MHz, CDCl₃) δ 7.40 - 7.17 (m, 9H), 6.14 - 6.11 (m, 1H), 5.29 (d, J = 9.8 Hz, 1H), 5.08 (dd, J = 8.5, 1.8 Hz, 1H), 4.59 (dd, J = 82.9, 15.0 Hz, 2H), 3.94 (d, J = 9.8 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 139.9, 135.32, 135.26, 131.3, 130.7, 129.5, 129.3, 129.1, 128.8, 128.1, 126.3, 107.3, 59.9, 52.7.

HRMS (ESI) for C₁₆H₁₅ClN₂NaO₂S [M+Na]⁺: calcd 357.0435, found 357.0437.

HPLC: Chiralcel AD-H column (250 mm); detected at 254 nm; hexane/*i*-propanol = 70/30; flow =0.7 mL/min; Retention time: 7.4 min, 8.8 min (major).



(S)-6-benzyl-3-(3-fluorophenyl)-3,6-dihydro-2H-1,2,6-thiadiazine 1,1-dioxide (3j)



White solid, 63 mg, 99% yield, 99% ee. $[\alpha]^{20}_{D} = -20.1$ (c 0.82, CHCl₃). ¹H NMR (300 MHz, CDCl₃) δ 7.40 - 7.29 (m, 6H), 7.09 - 6.95 (m, 3H), 6.12 (dd, J = 8.5, 2.0 Hz, 1H), 5.32 (d, J = 9.9 Hz, 1H), 5.09 (dd, J = 8.5, 1.9 Hz, 1H), 4.60 (dd, J = 83.8, 15.0 Hz, 2H), 3.92 (d, J = 9.9 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 163.3 (d, $J_{CF} = 246.1$ Hz), 140.4 (d, $J_{CF} = 7.0$ Hz), 135.4, 131.2, 131.0 (d, $J_{CF} = 8.1$ Hz), 129.3, 129.0,

128.7, 123.7 (d, $J_{CF} = 2.9$ Hz), 116.3 (d, $J_{CF} = 21.0$ Hz), 115.0 (d, $J_{CF} = 22.3$ Hz), 107.3, 59.9, 52.6. HRMS (ESI) for $C_{16}H_{16}FN_2O_2S$ [M+H]⁺: calcd 319.0911, found 319.0912.

HPLC: Chiralcel AD-H column (250 mm); detected at 254 nm; hexane/*i*-propanol = 70/30; flow =0.7 mL/min; Retention time: 7.3 min, 8.4 min (major).



(S)-6-benzyl-3-(3,5-dimethylphenyl)-3,6-dihydro-2H-1,2,6-thiadiazine 1,1-dioxide (3k)



White solid, 57.1 mg, 87% yield, 97% ee.
$$[\alpha]^{19}{}_{D} = -64.8$$
 (c 0.55, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 7.43 - 7.26 (m, 5H), 6.97 (d, $J = 5.6$ Hz, 1H), 6.85 (d, $J = 6.1$ Hz, 2H), 6.09 (dd, $J = 8.4$, 1.9 Hz, 1H), 5.24 (d, $J = 9.8$ Hz, 1H), 5.11 - 5.07 (m, 1H), 4.79 - 4.41 (m, 2H), 3.77 (d, $J = 9.8$ Hz, 1H), 2.30 (s, 3H), 2.29 (s, 3H). ¹³C NMR (150 MHz, CDCl₃) δ 139.1, 137.9, 135.5, 130.9, 130.6, 129.20,

129.15, 128.7, 125.6, 108.7, 60.5, 52.7, 21.6. HRMS (ESI) for $C_{18}H_{20}N_2NaO_2S\ [M+Na]^+:$ calcd 351.1138, found 351.1146.

HPLC: Chiralcel AD-H column (250 mm); detected at 254 nm; hexane/*i*-propanol = 70/30; flow =0.7 mL/min; Retention time: 10.6 min, 12.1 min (major).



(S)-6-benzyl-3-(o-tolyl)-3,6-dihydro-2H-1,2,6-thiadiazine 1,1-dioxide (31)



White solid, 55.9 mg, 89% yield, 99% ee. $[\alpha]^{20}_{D} = -4.4$ (c 0.50, CHCl₃). ¹H NMR (300 MHz, CDCl₃) δ 7.41 - 7.33 (m, 5H), 7.26 - 7.16 (m, 4H), 6.16 (dd, J = 8.6, 2.1 Hz, 1H), 5.57 (dt, J = 10.3, 1.9 Hz, 1H), 5.13 (dd, J = 8.6, 1.7 Hz, 1H), 4.61 (dd, J = 91.7, 15.0 Hz, 2H), 3.74 (d, J = 10.2 Hz, 1H), 2.45 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 137.7, 136.0, 135.6, 131.3, 131,2, 129.3, 129.2, 129.0, 128.6, 127.3, 126.8,

107.9, 57.1, 52.5, 19.1. HRMS (ESI) for C₁₇H₁₈N₂NaO₂S [M+Na]⁺: calcd 337.0981, found 337.0985.

HPLC: Chiralcel AD-H column (250 mm); detected at 254 nm; hexane/*i*-propanol = 70/30; flow =0.7 mL/min; Retention time: 6.9 min, 8.5 min (major).



(S)-6-benzyl-3-(naphthalen-1-yl)-3,6-dihydro-2H-1,2,6-thiadiazine 1,1-dioxide (3m)



White solid, 60.2 mg, 86% yield, 99% ee. $[\alpha]^{20}_{D} = 60.0$ (c 0.52, CHCl₃). ¹H NMR (300 MHz, CDCl₃) δ 8.17 (d, J = 8.2 Hz, 1H), 7.82 (t, J = 8.4 Hz, 2H), 7.56 - 7.29 (m, 9H), 6.19 - 6.08 (m, 2H), 5.23 (d, J = 8.5 Hz, 1H), 4.58 (dd, J = 89.1, 15.0 Hz, 2H), 4.01 (d, J = 10.3 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 135.6, 134.2, 133.4, 131.32, 131.28, 130.1, 129.2, 129.1, 128.9, 128.5, 127.3, 126.6, 125.8, 125.4, 123.6,

107.5, 56.7, 52.4. HRMS (ESI) for $C_{20}H_{18}N_2NaO_2S$ [M+Na]⁺: calcd 373.0981, found 373.0988.

HPLC: Chiralcel AD-H column (250 mm); detected at 254 nm; hexane/*i*-propanol = 70/30; flow =0.7 mL/min; Retention time: 9.0 min, 10.7 min (major).



(S)-6-benzyl-3-(naphthalen-2-yl)-3,6-dihydro-2H-1,2,6-thiadiazine 1,1-dioxide (3n)



White solid, 64.4 mg, 92% yield, 98% ee. $[\alpha]^{20}_{D}$ = -80.0 (c 0.47, CHCl₃). ¹H NMR (300 MHz, CDCl₃) δ 7.85 - 7.73 (m, 4H), 7.52 - 7.34 (m, 8H), 6.17 (dd, *J* = 8.5, 1.5 Hz, 1H), 5.50 (d, *J* = 9.9 Hz, 1H), 5.22 (dd, *J* = 8.5, 1.2 Hz, 1H), 4.64 (dd, *J* = 95.3, 14.9 Hz, 2H), 3.94 (d, *J* = 10.0 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 135.5, 135.3, 133.7, 133.6, 131.0, 129.4, 129.3, 129.1, 128.7, 128.4, 128.1, 127.10, 127.07,

127.0, 125.5, 108.0, 60.6, 52.7. HRMS (ESI) for $C_{20}H_{18}N_2NaO_2S$ [M+Na]⁺: calcd 373.0981, found 373.0984.

HPLC: Chiralcel AD-H column (250 mm); detected at 254 nm; hexane/*i*-propanol = 70/30; flow =0.7 mL/min; Retention time: 12.4 min, 14.5 min (major).



(S)-6-benzyl-3-(thiophen-3-yl)-3,6-dihydro-2H-1,2,6-thiadiazine 1,1-dioxide (30)

White solid, 30 mg, 49% yield, 98% ee. $[\alpha]^{20}{}_{D} = -45.2$ (c 0.91, CHCl₃). ¹H NMR (300 MHz, CDCl₃) δ 7.36 - 7.31 (m, 6H), 7.22 (s, 1H), 7.01 (d, J = 5.0 Hz, 1H), 6.06 (dd, J = 3.0 K, 2.1 Hz, 1H), 5.42 (d, J = 10.2 Hz, 1H), 5.14 (d, J = 8.5 Hz, 1H), 4.58 (dd, J = 78.6, 15.0 Hz, 2H), 3.92 (d, J = 10.2 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 138.8, 135.6, 130.6, 129.2, 128.9, 128.6, 127.4, 126.9, 123.8, 107.1, 55.8, 52.4. HRMS (ESI) for

 $C_{14}H_{15}N_2O_2S_2 \ [M+H]^+: \ calcd \ 307.0569, \ found \ 307.0570.$

HPLC: Chiralcel AD-H column (250 mm); detected at 254 nm; hexane/*i*-propanol = 70/30; flow =0.7 mL/min; Retention time: 8.8 min, 11.4 min (major).



(S)-6-benzyl-3-(furan-3-yl)-3,6-dihydro-2H-1,2,6-thiadiazine 1,1-dioxide (3p)

Bn_NSNH

Oil liquid, 45.2 mg, 76% yield, 99% ee. $[\alpha]^{19}_{D} = -39.8$ (0.25, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 7.40 - 7.32 (m, 7H), 6.36 (s, 1H), 6.05 (dd, J = 8.5, 2.1 Hz, 1H), 5.32 (d, J = 10.3 Hz, 1H), 5.06 (dd, J = 8.5, 1.7 Hz, 1H), 4.58 (dd, J = 98.4, 15.0 Hz, 2H), 3.88 (d, J = 10.1 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 144.3, 140.7, 135.5, 130.7,

129.2, 128.9, 128.6, 123.3, 109.6, 106.5, 52.7, 52.4. HRMS (ESI) for $C_{14}H_{14}N_2NaO_3S$ [M+Na]⁺: calcd 313.0617, found 313.0618.

HPLC: Chiralcel AD-H column (250 mm); detected at 254 nm; hexane/*i*-propanol = 70/30; flow =0.7 mL/min; Retention time: 8.9 min, 13.6 min (major).



(R)-6-benzyl-4-chloro-3-phenyl-3,6-dihydro-2H-1,2,6-thiadiazine 1,1-dioxide (3q)

O Bn N S NH ċι 3q

White solid, 63.5 mg, 95% yield, 99% ee. $[\alpha]^{20}_{D} = -39.6$ (c 0.90, CHCl₃). ¹H NMR (300 MHz, CDCl₃) & 7.43 - 7.26 (m, 8H), 7.07 - 7.04 (m, 2H), 6.32 (s, 1H), 5.15 (s, 1H), 4.59 (dd, J = 129.4, 14.7 Hz, 2H), 4.03 (s, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 135.6, 134.6, 129.8, 129.5, 129.4, 129.2, 129.1, 128.5, 116.9, 64.3, 53.8. HRMS (ESI) for C₁₆H₁₅ClN₂NaO₂S [M+Na]⁺: calcd 357.0435, found 357.0442.

HPLC: Chiralcel AD-H column (250 mm); detected at 224 nm; hexane/i-propanol = 80/20; flow =0.7 mL/min; Retention time: 11.9 min, 12.7 min (major).



Peak No.	Peak ID	Ret Time	Height	Area	Conc.
1		11.907	367755.906	7860545.500	49.3954
2		12.765	358201.250	8052961.500	50.6046
Total			725957.156	15913507.000	100.0000



1	11.907	1998.136	32004.951	0.2878	_
2	12.723	506555.250	11088934.000	99.7122	
Total		508553.386	11120938.951	100.0000	

(R)-6-benzyl-4-bromo-3-phenyl-3,6-dihydro-2H-1,2,6-thiadiazine 1,1-dioxide (3r)

 $\begin{array}{l} \text{White solid, 59.7 mg, 79\% yield, 99\% ee. } [\alpha]^{20}{}_{\mathrm{D}} = -37.4 \text{ (c } 0.85, \mathrm{CHCl}_3\text{)}. {}^{1}\mathrm{H} \ \mathrm{NMR} \\ \text{(300 MHz, CDCl}_3\text{)} \ \delta \ 7.47 - 7.32 \text{ (m, 8H)}, 7.09 - 7.06 \text{ (m, 2H)}, 6.44 \text{ (s, 1H)}, 5.20 \text{ (d, } J \\ = 9.0 \ \mathrm{Hz}, 1 \mathrm{H}\text{)}, 4.60 \ \mathrm{(dd, } J = 125.4, 14.8 \ \mathrm{Hz}, 2 \mathrm{H}\text{)}, 4.12 \ \mathrm{(d, } J = 8.9 \ \mathrm{Hz}, 1 \mathrm{H}\text{)}. {}^{13}\mathrm{C} \ \mathrm{NMR} \\ \text{(125 MHz, CDCl}_3\text{)} \ \delta \ 136.4, 134.7, 131.8, 129.8, 129.5, 129.3, 129.0, 128.5, 105.8, \\ \text{65.3, 53.5. HRMS (ESI) for } \mathrm{C}_{16}\mathrm{H}_{15}\mathrm{BrN}_{2}\mathrm{NaO}_{2}\mathrm{S} \ [\mathrm{M}+\mathrm{Na}]^{+}: \mathrm{calcd} \ 400.9930, \mathrm{found} \ 400.9936. \end{array}$

HPLC: Chiralcel AD-H column (250 mm); detected at 254 nm; hexane/*i*-propanol = 80/20; flow =0.7 mL/min; Retention time: 10.0 min, 11.1 min (major).



Peak No.	Peak ID	Ret Time	Height	Area	Conc.
1		9.965	325.027	4894.700	0.2516
2		11.097	112431.328	1940426.375	99.7484
Total			112756.355	1945321.075	100.0000

(R)-6-benzyl-3-phenyl-4-vinyl-3,6-dihydro-2H-1,2,6-thiadiazine 1,1-dioxide (3s)



White solid, 35.9 mg, 55% yield, 95% ee. $[\alpha]^{20}_{D} = -6.4$ (c 0.42, CHCl₃). ¹H NMR (300 MHz, CDCl₃) δ 7.41 - 7.32 (m, 9H), 7.25 - 7.23 (m, 1H), 6.23 (s, 1H), 6.00 (dd, J = 17.7, 11.3 Hz, 1H), 5.39 (d, J = 8.3 Hz, 1H), 4.78 (s, 1H), 4.62 (dd, J = 65.6, 4.0 Hz, 2H), 4.46 (d, J = 7.6 Hz, 1H), 4.14 (d, J = 8.2 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 137.7, 135.5, 133.3, 132.1, 129.32, 129.28, 129.1, 129.0, 128.7, 128.6,

118.3, 113.7, 61.2, 52.5. HRMS (ESI) for $C_{18}H_{19}N_2O_2S$ [M+H]⁺: calcd 327.1162, found 327.1170.

HPLC: Chiralcel IC column (250 mm); detected at 254 nm; hexane/*i*-propanol = 70/30; flow =0.7 mL/min; Retention time: 11.8 min, 22.1 min (major).



(R)-6-benzyl-3,4-diphenyl-3,6-dihydro-2H-1,2,6-thiadiazine 1,1-dioxide (3t)



White solid, 69.2 mg, 92% yield, 99% ee. $[\alpha]^{20}_{D} = -160.5$ (c 0.45, CHCl₃). ¹H NMR (300 MHz, CDCl₃) δ 7.46 - 7.36 (m, 5H), 7.21 - 7.05 (m, 8H), 7.00 - 6.97 (m, 2H), 6.34 (d, J = 1.2 Hz, 1H), 5.74 (d, J = 8.4 Hz, 1H), 4.67 (dd, J = 102.8, 15.0 Hz, 2H), 4.17 (d, J = 8.7 Hz, 1H). ¹³C NMR (125 MHz, CDCl₃) δ 137.5, 137.4, 135.5, 129.9, 129.3, 129.2, 129.1, 128.93, 128.87, 128.7, 127.2, 126.4, 120.2, 62.7, 52.7.

HRMS (ESI) for $C_{22}H_{20}N_2NaO_2S$ [M+Na]⁺: calcd 399.1138, found 399.1142.

HPLC: Chiralcel IC column (250 mm); detected at 224 nm; hexane/*i*-propanol = 70/30; flow =0.7 mL/min; Retention time: 14.1 min, 18.4 min (major).



(S)-3-(4-chlorophenyl)-6-methyl-3,6-dihydro-2H-1,2,6-thiadiazine 1,1-dioxide (3u)



White solid, 35.1 mg, 68% yield, 99% ee. $[\alpha]^{20}_{D} = -130.5$ (c 1.05, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 7.37 - 7.30 (m, 4H), 6.09 (dd, J = 8.5, 2.0 Hz, 1H), 5.33 (d, J = 9.8 Hz, 1H), 5.07 (dd, J = 8.5, 1.7 Hz, 1H), 4.13 (d, J = 9.8 Hz, 1H), 3.10 (s, 3H). ¹³C NMR (125 MHz, CDCl₃) δ 136.6, 135.2, 133.7, 129.6, 129.4, 105.7, 59.7, 36.0.

HRMS (ESI) for $C_{10}H_{10}ClN_2O_2S$ [M-H]⁻: calcd 257.0157, found 257.0166.

HPLC: Chiralcel AD-H column (250 mm); detected at 254 nm; hexane/*i*-propanol = 70/30; flow =0.7 mL/min; Retention time: 7.1 min, 7.6 min (major).



Peak No.	Peak ID	Ret Time	Height	Area	Conc.
1		7.070	130222.109	1628372.875	49.8222
2		7.590	120024.328	1639992.625	50.1778
Total			250246.438	3268365.500	100.0000



1	7.063	546.857	6348.032	0.5550	
2	7.582	83510.445	1137384.875	99.4450	
Total		84057.303	1143732.907	100.0000	

(S)-6-(4-methoxybenzyl)-3-phenyl-3,6-dihydro-2H-1,2,6-thiadiazine 1,1-dioxide (3v)



White solid, 64.7 mg, 98% yield, 99% ee. $[\alpha]^{20}_{D} = -34.1$ (c 1.23, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 7.35 - 7.32 (m, 5H), 7.25 (dd, J = 6.1, 2.0 Hz, 2H), 6.92 (d, J = 8.6 Hz, 2H), 6.11 (dd, J = 8.5, 2.0 Hz, 1H), 5.33 - 5.30 (m, 1H), 5.11 (dd, J = 8.5, 1.7 Hz, 1H), 4.54 (dd, J = 131.6, 14.7 Hz, 2H), 3.84 - 3.77 (m, 4H). ¹³C NMR (125

 $\label{eq:MHz, CDCl_3} \begin{array}{l} \delta \ 160.0, \ 138.1, \ 130.7, \ 130.6, \ 129.4, \ 129.3, \ 128.0, \ 127.4, \ 114.6, \ 108.2, \ 60.5, \ 55.7, \ 52.2. \\ \\ HRMS \ (ESI) \ for \ C_{17}H_{19}N_2O_3S \ [M+H]^+: \ calcd \ 331.1111, \ found \ 331.1117. \end{array}$

HPLC: Chiralcel AD-H column (250 mm); detected at 254 nm; hexane/*i*-propanol = 70/30; flow =0.7 mL/min; Retention time: 10.2 min, 11.6 min (major).



5. Construction of Chiral 1,3-diamines



Synthesis of (3*R***,5***S***)-3-allyl-2-benzyl-5-(4-methoxyphenyl)-1,2,6-thiadiazinane 1,1-dioxide (4): A 10 mL vessel was charged with the 1,2-adduct 3a** (66 mg, 0.20 mmol, 99% ee) in 2 mL DCM, then TFA (90 μL, 1.2 mmol, 6 equiv.) and allyltrimethylsilane (127 μL, 0.8 mmol, 4 equiv.) was added at 0 ° C and the reaction stirred at 0 ° C for 30 minutes. The reaction was diluted with NaHCO₃ (aq.), extracted with DCM, dried on anhydrous Na₂SO₄. The solvent was removed under vacuum and the residue was purified by silica gel column chromatography to afford the chiral allyl product **4** as white solid (71.4 mg, 96% yield, dr = 100: 0, 99% ee). $[\alpha]^{19}_{D}$ = 59.3 (c 0.22, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 7.40 - 7.23 (m, 7H), 6.89 (d, *J* = 8.7 Hz, 2H), 5.65 - 5.54 (m, 1H), 5.09 - 5.01 (m, 2H), 4.85 (dd, *J* = 13.6, 7.9 Hz, 1H), 4.45 (dd, *J* = 62.9, 14.4 Hz, 2H), 4.12 (d, *J* = 7.0 Hz, 1H), 3.80 (s, 3H), 3.42 - 3.36 (m, 1H), 2.89 - 2.61 (m, 2H), 1.91 - 1.83 (m, 2H). ¹³C NMR (150 MHz, CDCl₃) δ 159.9, 136.24, 135.5, 131.9, 129.08, 129.05, 128.4, 127.9, 118.3, 114.6, 57.5, 55.7, 55.2, 52.4, 35.4, 31.7. HRMS (ESI) for C₂₀H₂₄N₂NaO₃S [M+Na]⁺: calcd 395.1400, found 395.1397.

HPLC: Chiralcel IC column (250 mm); detected at 224 nm; hexane/*i*-propanol = 80/20; flow =0.7 mL/min; Retention time: 31.6 min (major), 44.8 min.





Tert-butyl-benzyl((1*S*,3*R*)-1-((*tert*-butoxycarbonyl)amino)-1-(4-methoxyphenyl)hex-5-en-3-yl)carb amate (5): A N₂ protected solution of 4 (37.2 mg, 0.1 mmol) in 1,3-propanediamine solvent was heated to reflux for 3 hours. The reaction was naturally cooled to room temperature, extracted with DCM, washed with water, dried on anhydrous Na₂SO₄ and removed the solvent under vacuum. The residue was dissolved in 2 mL DCM, NBS (2 mg, 0.01 mmol, 0.1 equiv.) and Boc₂O (44 mg, 0.2 mmol, 2 equiv.) was added and the reaction was stirred for 0.5 hour and purified by silica gel column chromatography to afford product **5** as colorless solid (26.5 mg, 52% yield, 99% ee). $[\alpha]^{19}{}_{\rm D}$ = -48.1 (c 0.12, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 7.34 - 7.27 (m, 5H), 7.09 - 6.80 (m, 4H), 5.54 (d, *J* = 7.1 Hz, 1H), 4.94 (d, *J* = 12.7 Hz, 2H), 4.67 - 4.31 (m, 3H), 4.15 - 4.11 (m, 1H), 3.97 - 3.80 (m, 4H), 2.26 (dd, *J* = 25.1, 17.8 Hz, 2H), 2.07 - 1.86 (m, 2H), 1.50 - 1.43 (m, 18H). ¹³C NMR (150 MHz, CDCl₃) δ 158.9, 139.8, 135.6, 128.7, 128.5, 127.9, 127.5, 127.3, 117.5, 114.2, 80.3, 79.7, 55.6, 52.0, 38.4, 30.0, 28.8, 28.7, 28.4. HRMS (ESI) for C₃₀H₄₂N₂NaO₅ [M+Na]⁺: calcd 533.2986, found 533.2989.

HPLC: Chiralcel AD-H column (250 mm); detected at 224 nm; hexane/*i*-propanol = 95/5; flow =0.5 mL/min; Retention time: 23.7 min (major), 27.1 min.





(*3R*,5*S*)-2-benzyl-3-(3-hydroxypropyl)-5-(4-methoxyphenyl)-1,2,6-thiadiazinane 1,1-dioxide (6): Compound 5 (110 mg, 0.3 mmol) was dissolved in 4 mL THF, borane-methyl sulfide complex (54 μL, 0.9 mmol, 3 equiv., 94%) was added at 0 °C and the reaction was stirred at room temperature for 3 hours. After reaction completion, diluted the reaction with NaOH (2M aq.) and H₂O₂ (30% aq.), extracted the reaction with EtOAc and dried on anhydrous Na₂SO₄, removed the solvent under vacuum and the residue was purified by silica gel column chromatography to afford alcohol **6** as white solid (86.5 mg, 75% yield). [α]¹⁹_D = 47.2 (c 0.26, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 7.45 - 7.36 (m, 5H), 7.30 - 7.27 (m, 2H), 6.93 (d, *J* = 8.7 Hz, 2H), 4.87 - 4.84 (m, 1H), 4.47 (dd, *J* = 125.2, 14.1 Hz, 2H), 4.17 (t, *J* = 6.1 Hz, 1H), 3.85 (s, 3H), 3.58 - 3.53 (m, 2H), 3.44 (dd, *J* = 13.6, 6.0 Hz, 1H), 2.44 - 2.33 (m, 1H), 2.08 - 1.99 (m, 1H), 1.74 - 1.60 (m, 4H). ¹³C NMR (125 MHz, CDCl₃) δ 160.0, 136.5, 132.2, 129.4, 129.1, 128.5, 128.0, 114.6, 62.7, 58.3, 55.73, 55.69, 54.1, 32.1, 30.1, 28.5. HRMS (ESI) for C₂₀H₂₆N₂NaO₄S [M+Na]⁺: calcd 413.1505, found 413.1500.

N-((*S*)-2-((*R*)-1-benzylpyrrolidin-2-yl)-1-(4-methoxyphenyl)ethyl)methanesulfonamide (7): The loohol intermediate **6** (39 mg, 0.1 mmol) was refluxed in 0.3 mL 1,3-propanediamine under N₂ atmosphere for 3 hours. Cooled the mixture to room temperature and extracted with DCM, washed with water, dried on anhydrous Na₂SO₄ and removed the solvent under vacuum. The ring-opening residue was dissolved in 1 mL DCM under N₂ atmosphere, TEA (28 µL, 0.2 mmol, 2 equiv.) and MsCl (16 µL, 0.2 mmol, 2 equiv.) were added at 0 °C. The mixture was stirred at room temperature for 3 h and diluted with water, extracted with DCM, washed with brine and dried on anhydrous Na₂SO₄. The solvent was removed and the residue was purified by silica gel column chromatography to afford the pyrrolidine product 7 as colorless solid (24.4 mg, 63% yield, 99% ee). [α]¹⁷_D = -28.1 (c 0.44, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 7.36 (dd, *J* = 9.7, 3.3 Hz, 4H), 7.30 - 7.24 (m, 3H), 6.87 (d, *J* = 8.6 Hz, 2H), 4.75 (dd, *J* = 10.8, 4.0 Hz, 1H), 4.12 (d, *J* = 13.1 Hz, 1H), 3.80 (s, 3H), 3.33 (d, *J* = 13.1 Hz, 1H), 3.13 - 3.09 (m, 1H), 2.89 - 2.85 (m, 1H), 2.39 (s, 3H), 2.25 - 2.19 (m, 1H), 2.03 - 1.96 (m, 4H), 1.80 - 1.74 (m, 1H), 1.67 (dt, *J* = 14.9, 3.9 Hz, 2H). ¹³C NMR (125 MHz, CDCl₃) δ 159.5, 138.8, 134.3, 129.2, 128.8, 128.7, 127.6, 114.4, 63.4, 59.5, 55.6, 55.5, 54.3, 42.7, 36.6, 28.3, 23.7. HRMS (ESI) for C₂₁H₂₉N₂O₃S [M+H]⁺: calcd 389.1893, found 389.1885.

HPLC: Chiralcel OZ-H column (250 mm); detected at 210 nm; hexane/*i*-propanol = 60/40; flow =0.7 mL/min; Retention time: 10.0 min (major), 13.4 min.



(*S*)-2-benzyl-5-phenyl-1,2,6-thiadiazinane 1,1-dioxide (8): A 10 mL vessel was charged with the 3b (60 mg, 0.20 mmol, 99% ee) in 2 mL DCM, then TFA (90 µL, 1.2 mmol, 6 equiv.) and triethylsilane (127 µL, 0.8 mmol, 4 equiv.) was added at 0 °C and the reaction stirred for another 30 minutes. The reaction was diluted with NaHCO₃ (aq.), extracted with DCM, dried on anhydrous Na₂SO₄. The solvent was removed and the residue was purified by silica gel column chromatography to afford product **8** as white solid (57.4 mg, 95% yield). $[\alpha]^{19}_{D} = 30.8$ (c 0.29, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 7.38 - 7.32 (m, 10H), 4.80 - 4.76 (m, 1H), 4.56 - 4.11 (m, 3H), 3.52 (td, *J* = 13.2, 2.7 Hz, 1H), 3.21 (ddd, *J* = 13.4, 4.2, 2.3 Hz, 1H), 2.04 - 1.93 (m, 1H), 1.85 (dd, *J* = 14.1, 2.6 Hz, 1H). ¹³C NMR (150 MHz, CDCl₃) δ 139.5, 135.7, 129.3, 129.2, 129.1, 128.9, 128.4, 126.6, 60.0, 52.2, 47.8, 29.6. HRMS (ESI) for C₁₆H₁₈N₂NaO₂S [M+Na]⁺: calcd 325.0981, found 325.0990.

Tert-butyl (*S*)-benzyl(3-((*tert*-butoxycarbonyl)amino)-3-phenylpropyl)carbamate (9): The reaction procedure was the same as the synthesis of product **5**. The reaction was purified by silica gel column chromatography to afford the chiral 1,3-diamine product **9** as colorless solid (49.5 mg, 68% yield, 99% ee). $[\alpha]^{19}{}_{\rm D} = 0.2$ (c 0.62, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 7.32 - 7.16 (m, 10H), 5.08 - 4.34 (m, 4H), 3.34 - 3.31 (m, 2H), 2.04 - 1.95 (m, 2H), 1.45 - 1.40 (s, 18H). ¹³C NMR (150 MHz, CDCl₃) δ 155.6, 138.7, 128.9, 128.8, 128.2, 127.6, 126.5, 80.2, 79.8, 53.1, 50.5, 44.5, 35.6, 28.8, 28.7. HRMS (ESI) for C₂₆H₃₆N₂NaO₄ [M+Na]⁺: calcd 463.2567, found 463.2579.

HPLC: Chiralcel OD-H column (250 mm); detected at 224 nm; hexane/*i*-propanol = 90/10; flow =0.7 mL/min; Retention time: 6.0 min (major), 9.3 min.





(S)-1,2,3,11b-tetrahydro-[1,2,6]thiadiazino[3,2-a]isoquinolin-7(6H)-one 4,4-dioxide (10): To a solution of product 8 (60 mg, 0.2 mmol) in 2 mL dry DMF was added K₂CO₃ (41.5 mg, 0.3 mmol, 1.5 equiv.) and tert-butyl bromoacetate (59 µL, 0.4 mmol, 2 equiv.) and the mixture was stirred at 60 °C for 2 hours. The reaction was diluted with water and extracted with EtOAc, washed with brine and dried on anhydrous Na₂SO₄. The solvent was removed and the residue was dissolved in 2 mL DCM, 0.4 mL TFA was added and the reaction was stirred for 3 hours. After reaction completion, diluted with NaHCO₃ (aq.), extracted with DCM, dried on anhydrous Na₂SO₄. The solvent was removed and the residue was dissolved in 2 mL dry DCM, a drop dry DMF was added, followed with oxalyl chloride (82 µL, 0.6 mmol, 3 equiv.) at 0 °C. The reaction was stirred at room temperature for 0.5 hour. Then the solvent was removed and the residue was dissolved in 2 mL dry DCM, AlCl₃ (54 mg, 0.4 mmol, 2 equiv.) was added and the reaction stirred at room temperature for 3 hours and purified by silica gel column chromatography to afford the cyclic product 10 as yellow solid (38.2 mg, 76% yield for 4 steps, 99% ee). $[\alpha]^{19}_{D} = 30.6$ (c 0.15, CHCl₃). ¹H NMR (400 MHz, DMSO) δ 7.95 (d, J = 7.7 Hz, 1H), 7.72 (t, J = 7.5 Hz, 1H), 7.58 (d, J = 7.7 Hz, 1H), 7.51 (t, J = 7.5 Hz, 1H), 7.28 (s, 1H), 5.20 - 5.17 (m, 1H), 4.00 (dd, J = 107.9, 17.0 Hz, 2H), 3.54 (t, J = 12.7 Hz, 1H), 3.36 - 3.33 (m, 1H), 1.88 (qd, J = 12.9, 4.6 Hz, 1H), 1.66 (d, J = 14.1 Hz, 1H). ¹³C NMR (125 MHz, DMSO) δ 190.9, 143.3, 134.8, 128.5, 128.1, 127.1, 126.1, 58.0, 50.2, 43.2, 24.0. HRMS (ESI) for C₁₁H₁₂N₂NaO₃S [M+Na]⁺: calcd 275.0461, found 275.0464.

HPLC: Chiralcel IC column (250 mm); detected at 224 nm; hexane/*i*-propanol = 60/40; flow =0.7 L/min; Retention time: 18.2 min (major), 38.5 min.



(4*R*,5*S*)-2-benzyl-4,5-diphenyl-1,2,6-thiadiazinane 1,1-dioxide (11): To a solution of 1,2-adduct 3t (20 mg, mmol) in 2 mL EA and 2 mL EtOH was added Pd/C (palladium 10% on Carbon)(10 mol%, 2 mg) under H₂ atmosphere. And the reaction was stirred at 40 °C for 6 h. The mixture was filtered and the solvent was removed, the residue was purified by silica gel column chromatography to afford the product 11 as white solid (82% yield, 16.4 mg, dr = 98:2, 99% ee). $[\alpha]^{17}_{D}$ = -27.7 (c 0.39, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 7.40 - 6.99 (m, 13H), 6.77 (dd, *J* = 6.5, 2.5 Hz, 2H), 5.35 (dd, *J* = 12.1, 3.3

Hz, 1H), 4.89 (t, J = 12.8 Hz, 2H), 3.77 (d, J = 13.6 Hz, 1H), 3.65 (dd, J = 12.4, 3.9 Hz, 1H), 3.40 (dd, J = 12.4, 1.6 Hz, 1H), 3.15 - 3.14 (m, 1H). ¹³C NMR (150 MHz, CDCl₃) δ 137.3, 137.0, 134.7, 130.0, 129.9, 129.7, 128.9, 128.6, 128.5, 128.4, 128.0, 127.7, 126.2, 62.6, 53.9, 52.7, 45.0. HRMS (ESI) for C₂₂H₂₂N₂NaO₂S [M+Na]⁺: calcd 401.1294, found 401.1295.

HPLC: Chiralcel AD-3 column (250 mm); detected at 224 nm; hexane/*i*-propanol = 80/20; flow =0.7 mL/min; Retention time: 14.5 min, 16.2 min, 17.2 min (major), 19.1 min.



Tert-butyl benzyl((2*R*,3*S*)-3-((*tert*-butoxycarbonyl)amino)-2,3-diphenylpropyl)carbamate (12): The reaction procedure was the same as the synthesis of product 5. The reaction was purified by silica gel column chromatography to afford the chiral 1,3-diamine product 12 as colorless solid (14.3 mg, 64% yield, 99% ee). $[\alpha]^{19}_{D} = 18.8$ (c 0.33, CHCl₃). ¹H NMR (400 MHz, CDCl₃) δ 7.26 - 7.23 (m, 10H),

7.10 - 7.00 (m, 5H), 4.96 - 4.69 (m, 2H), 4.25 - 3.76 (m, 2H), 3.52 - 3.27 (m, 3H), 1.37 (s, 9H), 1.27 (s, 9H). 13 C NMR (125 MHz, CDCl₃) δ 156.0, 155.4, 142.1, 138.4, 129.3, 128.8, 128.2, 127.64, 127.58, 127.53, 127.4, 127.1, 80.1, 79.9, 56.8, 51.4, 50.3, 49.4, 28.7, 28.6. HRMS (ESI) for C₃₂H₄₀N₂NaO₄ [M+Na]⁺: calcd 539.2880, found 539.2894.

HPLC: Chiralcel AD-H column (250 mm); detected at 224 nm; hexane/*i*-propanol = 95/5; flow =0.7 mL/min; Retention time: 13.2 min, 17.7 min (major).



6. Copies of ¹H NMR and ¹³C NMR spectra





























































